Simoa Antibody Quantitation via Paramagnetic Microbead Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting antibodies to infectious organisms, such as SARS-CoV-2, lack the sensitivity and specificity needed for accurate quantitation, particularly at low concentrations, and there is a need for improved diagnostic tools that can reliably measure immune responses to infectious diseases.
Innovation Solution
The development of a method and kit using a paramagnetic microbead-based sandwich ELISA, where a sample is contacted with an antigen or its fragment, and a detectable signal is assessed and compared to a calibration data set generated using a calibrator antibody, allowing for the quantitative detection of antibodies, specifically for SARS-CoV-2 using the Simoa HD-X Analyzer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional ELISA methods are used for antibody detection, then the assay can be performed with standard equipment and procedures, but the sensitivity is insufficient to detect low concentrations of antibodies accurately
Solution Approach 1:
The assay is segmented into distinct functional components: paramagnetic microbeads for antigen capture, isolation wells for single-molecule separation, and digital signal detection. This segmentation enables sensitivity improvement by isolating individual antibody-antigen complexes while maintaining procedural organization through defined assay stages.
Solution Approach 2:
Paramagnetic microbeads serve as intermediaries that capture antigens from the sample and present them for antibody binding. The microbeads mediate between the liquid sample and the solid support, enabling sensitive detection while simplifying the overall assay design through a single versatile reagent.
2Productivity
If the assay is designed for high throughput processing, then productivity increases, but the complexity of the device and protocol increases
Solution Approach 1:
The Simoa platform is designed as a universal system that can perform multiple functions: sample processing, antibody detection, quantitation, and data analysis all within a single instrument. This multi-functionality enables high throughput across different assay types without proportionally increasing operational complexity.
Solution Approach 2:
The assay protocol is designed to be self-guiding with automated bead dispensing, incubation timing, and signal detection. The system performs many steps automatically without requiring complex manual intervention at each stage, enabling high throughput while keeping the user interface simple.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides high sensitivity and specificity, enabling accurate quantitation of antibodies, aiding in the diagnosis of past or current infections and immune responses, with the Simoa COVID-19 IgG Antibody Test demonstrating 100% specificity and 90% sensitivity in initial studies.
Implementation Method 1
performing a paramagnetic microbead-based sandwich ELISA
Implementation Method 2
contacting a sample from a subject with an antigen of an infectious organism, or a fragment or analog thereof, to allow binding between an antibody to said antigen of said infectious organism
Implementation Method 3
At very low analyte concentrations, Poisson statistics predict that bead-containing microwells in the array will contain either a single labeled analyte molecule or no analyte molecules
Implementation Method 4
buildup of fluorescent product from an enzyme label, so that signal from a single immunocomplex can be readily detected with a CCD camera
Data Source
AI summary
The present disclosure relates to methods and compositions, e.g., kits, for quantitatively detecting an antibody of a subject to an infectious organism. In some embodiments, the present disclosure provides for methods and compositions, e.g., kits, for quantitatively detecting a human antibody to SARS-CoV-2 polypeptide or S (spike) polypeptide. Certain applications and uses of the present methods and compositions, e.g., kits, are also provided.